시장보고서
상품코드
1268029

MC4R(멜라노코르틴 4 수용체) 경로 : 파이프라인 애널리틱스(2023년)

MC4R Pathway-Pipeline Analytics -2023

발행일: | 리서치사: Mellalta Meets LLP | 페이지 정보: 영문 61 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

MC4R(멜라노코르틴 4 수용체) 경로에 대해 조사했으며, MC4R 경로의 개요와 파이프라인 동향, 경쟁 구도 및 파이프라인 약제 개요 등을 정리하여 전해드립니다.

목차

개요

MC4R 경로 표적

  • 서론
  • 유전학
  • MC4R 결손증
  • 작용기서
  • MC4R 저해제의 임상 응용

MC4R 경로 파이프라인 분석, 상별

  • MC4R 경로 개발, 개요
  • 파이프라인 제품, 개발 단계별
  • MC4R 경로의 경쟁 구도, 상별
  • 파이프라인 제품, 기업별
  • 파이프라인 제품, 적응증 및 상별
  • MC4R 경로의 단독요법과 병용요법 임상시험
  • MC4R 경로 - 자산, 적응증 및 상별
  • MC4R 경로 임상 및 규제 스케줄
  • 후기 단계 프로파일 비교의 개요

MC4R 경로 라이선싱, 인수 및 협업 계약

MC4R 경로 파이프라인 상황

  • MC4R 경로 파이프라인 약제 개요

제III상

  • Setmelanotide(Rhythm Pharmaceuticals, Inc)
  • Lorcaserin(Eisai Inc.)
  • PL9643(Palatin Technologies)

제II상

  • Bremelanotide(Palatin Technologies)

제I상

  • PF-07258669(Pfizer)
  • TCMCB 07(Endevica Bio)
  • LR19021(LG Life Sciences)
  • 전임상
  • PL9654(Palatin Technologies)

MC4R 경로 SWOT 분석

부록

KSA 23.05.18

The MC4R Pathway pipeline report covers the MC4R Pipeline market opportunity providing Key Competitive Analysis, 6 Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. In addition, our report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, mechanism of action, intervention types. The MC4R Pipeline report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

The MC4R pathway refers to a signalling cascade that is initiated by the binding of certain ligands, such as alpha-melanocyte-stimulating hormone (α-MSH), to the melanocortin 4 receptor (MC4R). This receptor is expressed in various regions of the brain, including the hypothalamus, and plays a critical role in regulating appetite and energy balance. Activation of the MC4R pathway leads to downstream effects that increase energy expenditure and decrease food intake, ultimately resulting in weight loss. This pathway has been the subject of significant research, as mutations in the MC4R gene have been linked to obesity in humans. Targeting the MC4R pathway may represent a promising strategy for the development of new treatments for obesity and related metabolic disorders.

In this report, Mellalta Meets provides an in-depth analysis of MC4R Pipeline covering Phase III , Phase II & Phase I Pipeline Analysis Overview, Pipeline Products by Stage of Development , MC4R Pipeline Competitive Landscape Distinguished by Phase & Route and molecule type, Clinical Pipeline Products by Company, Pipeline Assets by Indication and Phases, MC4R Pipeline Monotherapy & Combinations Clinical Trials, MC4R Pipeline Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are 8 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are Pfizer, Eisai. Inc., Rhythm Pharmaceuticals, Inc., Palatin Technologies, and Endevica Bio which have a robust clinical pipeline of MC4R Pathway candidates.

As per analysis, the development pipeline is full of molecules like small molecules, and peptides

Key Highlights of the MC4R Pathway Report:

  • There are XX products each in the Phase 3 and Phase 1 stage of development, representing XX% of the total share of the developing MC4R Pathway landscape.
  • The pipeline of MC4R pathway is dominated by biotech companies headquartered in United States with US companies holding the 4 positions. They represent XX% of all the MC4R pipeline.
  • MC4R Pathway pipeline landscape includes 100% of Monotherapy trials.
  • The pipeline of MC4R Pathway is dominated by Phase 3 (3) and Phase 1(3) followed by Phase 2 (1), and pre-clinical (1) assets.

Report Coverage:

  • Indication Prioritisation: MC4R Pathway market potential based on Indications.
  • Business Transactions & Strategies: Key collaborations and deal values
  • MC4R Pathway Pipeline Development: Product Profiles, Clinical Trials & Results
  • MC4R Pathway Acquisition Targets
  • MC4R Pathway Competitive Intelligence
  • Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The MC4R Pathway Target BACKGROUND

  • Introduction
  • Genetics
  • MC4R Deficiency
  • Mechanism of Action
  • Clinical Application of MC4R Inhibitors

MC4R Pathway PIPELINE ANALYSIS by Phases

  • MC4R Pathway Development - Overview
  • Pipeline Products by Stage of Development
  • MC4R Pathway Competitive Landscape by Phases
  • Pipeline Products by Company
  • Pipeline Products by Indication and Phases
  • MC4R Pathway Monotherapy & Combinations Clinical Trials
  • MC4R Pathway- Assets by Indication/Phase
  • MC4R Pathway Clinical & Regulatory Timelines
  • Late-Stage Profiles Comparisons At-a-glance

MC4R Pathway LICENSING, ACQUISITION, AND COLLABORATION DEALS

  • MC4R Pathway Licensing, Acquisition, and Deal values
  • MC4R Pathway Licensing by Transaction type and total amount size by Phases

MC4R Pathway Pipeline Landscape

  • MC4R Pathway Pipeline Drug Profiles

Phase III

  • Setmelanotide (Rhythm Pharmaceuticals, Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Lorcaserin (Eisai Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • PL9643 (Palatin Technologies)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments

Phase II

  • Bremelanotide (Palatin Technologies)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments

Phase I

  • PF-07258669 (Pfizer)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • TCMCB 07 (Endevica Bio)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • LR19021 (LG Life Sciences)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • Preclinical
  • PL9654 (Palatin Technologies)
    • Product Profile & Description
    • Collaborations
    • Other Developments

MC4R Pathway SWOT Analysis

Appendix

  • About us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제